Topic 447: Development and testing of a non-invasive cryo-device to prevent chemotherapy-induced peripheral neuropathy in hands and feet of cancer patients receiving Taxol for breast cancer.
Topic 447: Development and testing of a non-invasive cryo-device to prevent chemotherapy-induced peripheral neuropathy in hands and feet of cancer patients receiving Taxol for breast cancer.
批准号:
10928476
负责人:
Carole Spangler Vaughn
金额:
$39.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-09-11 至 2024-09-10
关键词:
Adverse eventBladderBody TemperatureBreast Cancer PatientCancer PatientChemotherapy-induced peripheral neuropathyClinicClinical ResearchComputer softwareDataDevelopmentDevice SafetyDevicesDocumentationFeedbackHandHealth PersonnelHomeHourHuman Subject ResearchInfusion proceduresInstitutional Review BoardsInstructionLimb structureLiquid substanceLocationMeasurementPaclitaxelPainPatientsPhasePreventionProductionProgress ReportsPumpQuality of lifeRecommendationReportingRiskRunningSerious Adverse EventSkinSpecific qualifier valueStatistical Data InterpretationSurveysSystemSystems IntegrationTemperatureTemperature SenseTestingTherapeuticTimeTrainingValidationVariantWeightchemotherapycohortcold temperaturedesignefficacy studyfootheat exchangerhuman subjectimpressionimprovedmalignant breast neoplasmnext generationoperationportabilitypreventprototyperecruitsafety studyscreeningusabilitywillingness
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The objective of this proposal is to develop a prototype device capable of cooling extremities to a level sufficient for prevention of chemotherapy-induced peripheral neuropathy (CIPN). Such a product will enable healthcare providers to make available a solution to prevent the physical pain and reduction in quality of life resulting from CIPN. The following Aims will be completed: (1) design, build, and validate prototypes, and (2) conduct usability and tolerability studies in a small patient cohort undergoing chemotherapy. The end of project deliverable is a validated Medacool™ prototype device with adjustable temperature within a tolerable therapeutic range with the ability to cool to therapeutic levels for 8+ hours. Through user feedback acquired in partnership with Eminence Clinical Research, Inc., the device will demonstrate ease of use in performing all critical tasks with no critical faults. The study will further provide initial indications of tolerability as well as aid in the design of a next generation prototype amenable to in-clinic, in-transit, and in-home portability for a planned Phase II pivotal efficacy and safety study in 250 patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金